» Articles » PMID: 19306173

Relationship Between Volume, Dose and Local Control in Stereotactic Radiosurgery of Brain Metastasis

Overview
Journal Br J Neurosurg
Specialty Neurosurgery
Date 2009 Mar 24
PMID 19306173
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study is to analyse the efficacy of linear accelerator stereotactic radiosurgery (SRS) on prognostic factors, local control rate and survival in patients with brain metastasis. Patients with either a single metastasis or up to 4 multiple brain metastases with a maximum tumour diameter of 40 mm for each tumour and a Karnofsky Performance Status (KPS) > or = 70 were eligible for SRS. SRS was applied to 150 lesions in 86 consecutive patients with a median age of 60 years (median 1 and mean 1.7 lesions per patient, mean KPS 86). Median overall survival was 6.2 months after SRS and 9.7 months from diagnosis of brain metastasis. Multivariate analysis revealed that a KPS of 90 or more (p = 0.009) and female sex (p = 0.003) were associated with a longer survival. Radiation dose < or = 15 Gy (p = 0.017) and KPS < 90 (p = 0.013) were independent predictors of a shorter time to local failure. Five patients showed evidence of radionecrosis with a median survival of 14.8 months. Addition of WBRT neither led to improvement of survival nor to improvement of local control. Improved local control following SRS for brain metastases was associated with KPS > or =90, a radiation dose > 15 Gy and a PTV < 13 cc. The potential of hypofractionated stereotactic radiotherapy (SRT) for brain metastases of larger volume warrants further study.

Citing Articles

Short-term predictors of stereotactic radiosurgery outcome for untreated single non-small cell lung cancer brain metastases: a restrospective cohort study.

Neto E, de Almeida Bastos D, Yoshikawa M, Figueiredo E, Souza Filho F, Prabhu S Neurosurg Rev. 2024; 47(1):172.

PMID: 38639882 DOI: 10.1007/s10143-024-02415-y.


The dosimetric parameters impact on local recurrence in stereotactic radiotherapy for brain metastases.

Berthet C, Lucia F, Bourbonne V, Schick U, Lecouillard I, Le Deroff C Br J Radiol. 2024; 97(1156):820-827.

PMID: 38377402 PMC: 11025672. DOI: 10.1093/bjr/tqae029.


Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure.

Leu J, Akerman M, Mendez C, Lischalk J, Carpenter T, Ebling D Front Oncol. 2023; 13:1132777.

PMID: 37091181 PMC: 10113671. DOI: 10.3389/fonc.2023.1132777.


Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.

Hui C, Wu Y, Liu K, Sandhu N, Blomain E, Binkley M Cureus. 2022; 14(11):e31838.

PMID: 36579260 PMC: 9788920. DOI: 10.7759/cureus.31838.


Open Source Repository and Online Calculator of Prediction Models for Diagnosis and Prognosis in Oncology.

Halilaj I, Oberije C, Chatterjee A, van Wijk Y, Mohammadian Rad N, Galganebanduge P Biomedicines. 2022; 10(11).

PMID: 36359199 PMC: 9687260. DOI: 10.3390/biomedicines10112679.